| [1] |
THACKER PD. Set a microbe to kill a microbe: drug resistance renews interest in phage therapy[J]. JAMA, 2003, 290(24):3183-3185. DOI: 10.1001/jama.290.24.3183.
|
| [2] |
SUMMERS WC. Bacteriophage therapy[J]. Annu Rev Microbiol, 2001, 55:437-451. doi: 10.1146/annurev.micro.55.1.437
|
| [3] |
安瑞.噬菌体治疗的前世、今生与未来——对话微生物学界噬菌体专家[J].科学通报, 2017, 62(23):2577-2580. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=kxtb201723001
AN R. Phage-based and future:dialogue bacteriophage expert in microbiology[J].Chin Sci Bulletin, 2017, 62(23):2577-2580. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=kxtb201723001
|
| [4] |
BOUCHER HW, TALBOT GH, BRADLEY JS, et al. Bad bugs, no drugs: no ESKAPE! an update from the Infectious Diseases Society of America[J]. Clin Infect Dis, 2009, 48(1):1-12. DOI: 10.1086/595011.
|
| [5] |
SUAY-GARCÍA B, PÉREZ-GRACIA MT. Future prospects for neisseria gonorrhoeae treatment[J]. Antibiotics (Basel), 2018, 7(2): E49. DOI: 10.3390/antibiotics7020049.
|
| [6] |
RHOADS DD, WOLCOTT RD, KUSKOWSKI MA, et al. Bacteriophage therapy of venous leg ulcers in humans: results of a phase Ⅰ safety trial[J]. J Wound Care, 2009, 18(6):237-238, 240-243. doi: 10.12968/jowc.2009.18.6.42801
|
| [7] |
WRIGHT A, HAWKINS CH, ANGGÅRD EE, et al.A controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to antibiotic-resistant pseudomonas aeruginosa; a preliminary report of efficacy[J]. Clin Otolaryngol, 2009, 34(4):349-357. DOI: 10.1111/j.1749-4486.2009.01973.x.
|
| [8] |
JAULT P, LECLERC T, JENNES S, et al. Efficacy and tolerability of a cocktail of bacteriophages to treat burn wounds infected by pseudomonas aeruginosa (PhagoBurn): a randomised, controlled, double-blind phase 1/2 trial[J]. Lancet Infect Dis, 2019, 19(1):35-45. DOI: 10.1016/S1473-3099(18)30482-1.
|
| [9] |
SARKER SA, MCCALLIN S, BARRETTO C, et al. Oral T4-like phage cocktail application to healthy adult volunteers from Bangladesh[J]. Virology, 2012, 434(2):222-232. DOI: 10.1016/j.virol.2012.09.002.
|
| [10] |
SARKER SA, SULTANA S, REUTELER G, et al. Oral phage therapy of acute bacterial diarrhea with two coliphage preparations: a randomized trial in children from Bangladesh[J]. EBioMedicine, 2016, 4:124-137. DOI: 10.1016/j.ebiom.2015.12.023.
|
| [11] |
SARKER SA, BERGER B, DENG Y, et al. Oral application of escherichia coli bacteriophage: safety tests in healthy and diarrheal children from Bangladesh[J]. Environ Microbiol, 2017, 19(1):237-250. DOI: 10.1111/1462-2920.13574.
|
| [12] |
首例超级细菌感染患者经噬菌体治疗痊愈[EB/OL].(2018-08-15).http://www.sh.chinanews.com/yljk/2018-08-15/43418.shtml.
|
| [13] |
LEE KC, JOORY K, MOIEMEN NS. History of burns: the past, present and the future[J]. Burns Trauma, 2014, 2(4):169-180. DOI: 10.4103/2321-3868.143620.
|
| [14] |
BARTOLETTI M, GIANNELLA M, TEDESCHI S, et al. Multidrug-resistant bacterial infections in solid organ transplant candidates and recipients[J]. Infect Dis Clin North Am, 2018, 32(3):551-580. DOI: 10.1016/j.idc.2018.04.004.
|
| [15] |
FLORESCU DF, MCCARTNEY AM, QIU F, et al. Staphylococcus aureus infections after liver transplantation[J]. Infection, 2012, 40(3):263-269. DOI: 10.1007/s15010-011-0224-3.
|
| [16] |
SHIELDS RK, CLANCY CJ, MINCES LR, et al. Staphylococcus aureus infections in the early period after lung transplantation: epidemiology, risk factors, and outcomes[J]. J Heart Lung Transplant, 2012, 31(11):1199-1206. DOI: 10.1016/j.healun.2012.08.012.
|
| [17] |
GIANNELLA M, BARTOLETTI M, MORELLI MC, et al. Risk factors for infection with carbapenem-resistant Klebsiella pneumoniae after liver transplantation: the importance of pre- and posttransplant colonization[J]. Am J Transplant, 2015, 15(6):1708-1715. DOI: 10.1111/ajt.13136.
|
| [18] |
FREIRE MP, OSHIRO IC, PIERROTTI LC, et al. Carbapenem-resistant enterobacteriaceae acquired before liver transplantation: impact on recipient outcomes[J]. Transplantation, 2017, 101(4):811-820.DOI: 10.1097/TP.0000000000001620.
|
| [19] |
MCDERMOTT H, SKALLY M, O'ROURKE J, et al. Vancomycin-resistant enterococci (VRE) in the intensive care unit in a nonoutbreak setting: identification of potential reservoirs and epidemiological associations between patient and environmental VRE[J]. Infect Control Hosp Epidemiol, 2018, 39(1):40-45. DOI: 10.1017/ice.2017.248.
|
| [20] |
KAMPMEIER S, KOSSOW A, CLAUSEN LM, et al. Hospital acquired vancomycin resistant enterococci in surgical intensive care patients-a prospective longitudinal study[J]. Antimicrob Resist Infect Control, 2018, 7:103. DOI: 10.1186/s13756-018-0394-1.
|
| [21] |
BANACH DB, PEAPER DR, FORTUNE BE, et al. The clinical and molecular epidemiology of pre-transplant vancomycin-resistant enterococci colonization among liver transplant recipients[J]. Clin Transplant, 2016, 30(3):306-311. DOI: 10.1111/ctr.12690.
|
| [22] |
TIMSIT JF, BASSETTI M, CREMER O, et al. Rationalizing antimicrobial therapy in the ICU:a narrative review[J]. Intensive Care Med, 2019, 45(2):172-189. DOI: 10.1007/s00134-019-05520-5.
|
| [23] |
BODRO M, SABÉ N, TUBAU F, et al. Extensively drug-resistant pseudomonas aeruginosa bacteremia in solid organ transplant recipients[J]. Transplantation, 2015, 99(3):616-622. DOI: 10.1097/TP.0000000000000366.
|
| [24] |
LIU T, ZHANG Y, WAN Q. Pseudomonas aeruginosa bacteremia among liver transplant recipients[J]. Infect Drug Resist, 2018, 11:2345-2356. DOI: 10.2147/IDR.S180283.
|
| [25] |
AGUIAR EB, MACIEL LC, HALPERN M, et al. Outcome of bacteremia caused by extended-spectrum β-lactamase-producing enterobacteriaceae after solid organ transplantation[J]. Transplant Proc, 2014, 46(6):1753-1756. DOI: 10.1016/j.transproceed.2014.05.003.
|
| [26] |
ESPINAR MJ, MIRANDA IM, COSTA-DE-OLIVEIRA S, et al. Urinary tract infections in kidney transplant patients due to escherichia coli and Klebsiella pneumoniae-producing extended-spectrum β-lactamases: risk factors and molecular epidemiology[J].PLoS One, 2015, 10(8):e0134737. DOI: 10.1371/journal.pone.0134737.
|
| [27] |
BAKTASH A, TERVEER EM, ZWITTINK RD, et al. Mechanistic insights in the success of fecal microbiota transplants for the treatment of clostridium difficile infections[J]. Front Microbiol, 2018, 9:1242. DOI: 10.3389/fmicb.2018.01242.
|
| [28] |
BOODMAN E. To save a young woman besieged by superbugs, scientists hunt a killer virus [EB/OL]. (2017-11-10). https://www.statnews.com/2017/11/10/superbug-phage-mallory-smith.
|
| [29] |
BOODMAN E. A patient's legacy: researchers work to make phage therapy less of a long shot [EB/OL]. (2017-11-28).https://www.statnews.com/2017/11/28/phage-therapy-mallory-smith.
|
| [30] |
ASLAM S YG, DAN J, REED S, et al. 373 - bacteriophage treatment in a lung transplant recipient in: 38th Annual International Society for Heart & Lung Transplantation (ISHLT) Meeting & Scientific Sessions, April 13, 2018[C]. France : Nice, 2018.
|
| [31] |
HO YH, TSENG CC, WANG LS, et al. Application of bacteriophage-containing aerosol against nosocomial transmission of carbapenem-resistant acinetobacter baumannii in an intensive care unit[J]. PLoS One, 2016, 11(12):e0168380. DOI: 10.1371/journal.pone.0168380.
|
| [32] |
GÓRSKI A, DĄBROWSKA K, MIĘDZYBRODZKI R, et al. Phages and immunomodulation[J]. Future Microbiol, 2017, 12:905-914. DOI: 10.2217/fmb-2017-0049.
|
| [33] |
ALIBERTI S, REYES LF, FAVERIO P, et al. Global initiative for meticillin-resistant staphylococcus aureus pneumonia (GLIMP): an international, observational cohort study[J]. Lancet Infect Dis, 2016, 16(12):1364-1376. DOI: 10.1016/S1473-3099(16)30267-5.
|
| [34] |
LO DK, MUHLEBACH MS, SMYTH AR. Interventions for the eradication of meticillin-resistant staphylococcus aureus (MRSA) in people with cystic fibrosis[J]. Cochrane Database Syst Rev, 2018, 7:CD009650.DOI: 10.1002/14651858.CD009650.pub4.
|
| [35] |
RODRÍGUEZ-SEVILLA G, GARCÍA-COCA M, ROMERA-GARCÍA D, et al. Non-tuberculous mycobacteriamultispecies biofilms in cystic fibrosis: development of an in vitro mycobacterium abscessus and pseudomonas aeruginosa dual species biofilm model[J]. Int J Med Microbiol, 2018, 308(3):413-423.DOI: 10.1016/j.ijmm.2018.03.003.
|
| [36] |
GRANCHELLI AM, ADLER FR, KEOGH RH, et al. Microbial interactions in the cystic fibrosis airway[J]. J Clin Microbiol, 2018, 56(8):e00354-e00318. DOI: 10.1128/JCM.00354-18.
|
| [37] |
ARROYO V, MOREAU R, KAMATH PS, et al. Acute-on-chronic liver failure in cirrhosis[J]. Nat Rev Dis Primers, 2016, 2:16041. DOI: 10.1038/nrdp.2016.41.
|
| [38] |
EKSER B, MANGUS RS. Spontaneous bacterial peritonitis[J]. Lancet, 2017, 389(10070):735. DOI: 10.1016/S0140-6736(16)30782-6.
|
| [39] |
BLAIR BM. Safe living following solid organ transplantation[J]. Surg Clin North Am, 2019, 99(1):153-161. DOI: 10.1016/j.suc.2018.09.011.
|
| [40] |
PENG H, CHEN IA. Rapid colorimetric detection of bacterial species through the capture of gold nanoparticles by chimeric phages[J]. ACS Nano, 2019, 13(2):1244-1252. DOI: 10.1021/acsnano.8b06395.
|
| [41] |
YUE H, HE Y, FAN E, et al. Label-free electrochemiluminescent biosensor for rapid and sensitive detection of pseudomonas aeruginosa using phage as highly specific recognition agent[J]. Biosens Bioelectron, 2017, 94:429-432.DOI: 10.1016/j.bios.2017.03.033.
|
| [42] |
HE Y, SHI Y, LIU M, et al. Nonlytic recombinant phage tail fiber protein for specific recognition of pseudomonas aeruginosa[J]. Anal Chem, 2018, 90(24):14462-14468. DOI: 10.1021/acs.analchem.8b04160.
|
| [43] |
FAROOQ U, YANG Q, ULLAH MW, et al. Bacterial biosensing: recent advances in phage-based bioassays and biosensors[J]. Biosens Bioelectron, 2018, 118:204-216. DOI: 10.1016/j.bios.2018.07.058.
|
| [44] |
BROGAN DM, MOSSIALOS E. A critical analysis of the review on antimicrobial resistance report and the infectious disease financing facility[J]. Global Health, 2016, 12:8. DOI: 10.1186/s12992-016-0147-y.
|
| [45] |
KILCHER S, LOESSNER MJ. Engineering bacteriophages as versatile biologics[J]. Trends Microbiol, 2019, 27(4):355-367. DOI: 10.1016/j.tim.2018.09.006.
|
WeChat Subscription Account
Wechat Service Account
Supported by:
Beijing Renhe Information Technology Co. Ltd
DownLoad: